Reference is made to the stock exchange release from
Our view is that the proposal to merge with APIM is both poorly conceived and not in the best interest of shareholders of
We are also questioning whether shareholders are best served by continuing a strategy exclusively focused on early-stage oncology R&D – a strategy which historically has been extremely detrimental to shareholder values. The combination of these factors leads us to our conclusion that the merger proposal lacks the necessary financial and strategic rationale for shareholders in
Contacts
Rachid Bendriss , co-CEO, (+47) 926 60 603, rb@northenergy.no
© NTB Norway, source